Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1990-7-13
|
pubmed:abstractText |
Adjuvant chemotherapy is a well accepted concept in the treatment of breast cancer and has resulted in most clinical studies in a significant prolongation of the disease-free interval in certain subgroups of patients. However, very little is known about the late effects of adjuvant chemotherapy and its influence upon the function of a series of physiologic mechanisms. In the present paper, a review of our studies on the influence of adjuvant chemotherapy consisting of cyclophosphamide, methotrexate and fluoruracil (CMF) upon the function of B, T and natural killer (NK) cells is given. It is shown that CMF adversely influenced primary antibody production following vaccination for a prolonged period of time after the termination of CMF treatment. In investigating T cell function, it was found that the administration of CMF led also to a similarly prolonged impairment of phytohemagglutinin (PHA-)stimulated soluble interleukin 2 receptor (sIL-2R) production and to a decrease in the proliferation of peripheral blood mononuclear cells following mitogenic stimulation with PHA. Finally, NK cell activity was found to be decreased for such a prolonged period of time after the termination of CMF treatment, too. We thus conclude that the administration of CMF in the adjuvant setting leads to a pronounced and prolonged impairment of certain immune mechanisms.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0303-8173
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
11-4
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:2353562-Antibody Formation,
pubmed-meshheading:2353562-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2353562-B-Lymphocytes,
pubmed-meshheading:2353562-Breast Neoplasms,
pubmed-meshheading:2353562-Combined Modality Therapy,
pubmed-meshheading:2353562-Cyclophosphamide,
pubmed-meshheading:2353562-Female,
pubmed-meshheading:2353562-Fluorouracil,
pubmed-meshheading:2353562-Follow-Up Studies,
pubmed-meshheading:2353562-Humans,
pubmed-meshheading:2353562-Immune Tolerance,
pubmed-meshheading:2353562-Killer Cells, Natural,
pubmed-meshheading:2353562-Lymphocyte Activation,
pubmed-meshheading:2353562-Methotrexate,
pubmed-meshheading:2353562-Receptors, Interleukin-2,
pubmed-meshheading:2353562-T-Lymphocytes
|
pubmed:year |
1990
|
pubmed:articleTitle |
Effects of adjuvant chemotherapy on specific and non-specific immune mechanisms.
|
pubmed:affiliation |
IInd Department of Medicine, University Hospital, Austria.
|
pubmed:publicationType |
Journal Article
|